Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of BMN 110 in Morquio A syndrome
NL-OMON35977Phase 3Withdrawn
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Jul 2011
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of elosulfase alfa in Mucopolysaccharidosis type IV A, sponsored by BioMarin Pharmaceutical Inc. Primary endpoints: Long-term safety of BMN 110, Long-term efficacy by endurance and 6 more. Planned start Jul 2011; status: withdrawn.
02
Drugs
elosulfase alfa
03
Conditions
Mucopolysaccharidosis type IV A
Beyond the preview
Go deeper on NL-OMON35977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35977.